$109.47
2.70% today
Nasdaq, May 02, 06:47 pm CET
ISIN
US64125C1099
Symbol
NBIX

Neurocrine Biosciences, Inc. Target price 2025 - Analyst rating & recommendation

Neurocrine Biosciences, Inc. Classifications & Recommendation:

Buy
85%
Hold
15%

Neurocrine Biosciences, Inc. Price Target

Target Price $157.63
Price $106.59
Potential
Number of Estimates 24
24 Analysts have issued a price target Neurocrine Biosciences, Inc. 2026 . The average Neurocrine Biosciences, Inc. target price is $157.63. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 27 analysts: 23 Analysts recommend Neurocrine Biosciences, Inc. to buy, 4 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Neurocrine Biosciences, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Neurocrine Biosciences, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Billion $ 2.36 2.65
24.81% 12.62%
EBITDA Margin 26.50% 22.33%
20.17% 15.73%
Net Margin 13.88% 15.03%
6.72% 8.25%

23 Analysts have issued a sales forecast Neurocrine Biosciences, Inc. 2025 . The average Neurocrine Biosciences, Inc. sales estimate is

$2.7b
Unlock
. This is
12.62% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$2.7b 15.97%
Unlock
, the lowest is
$2.6b 8.78%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $2.4b 24.81%
2025
$2.7b 12.62%
Unlock
2026
$3.1b 15.78%
Unlock
2027
$3.5b 13.72%
Unlock
2028
$3.9b 12.66%
Unlock
2029
$4.1b 4.91%
Unlock

8 Analysts have issued an Neurocrine Biosciences, Inc. EBITDA forecast 2025. The average Neurocrine Biosciences, Inc. EBITDA estimate is

$592m
Unlock
. This is
2.90% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$844m 38.33%
Unlock
, the lowest is
$412m 32.47%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $624m 49.99%
2025
$592m 5.08%
Unlock
2026
$855m 44.35%
Unlock
2027
$1.2b 45.38%
Unlock
2028
$1.5b 19.88%
Unlock
2029
$1.7b 17.11%
Unlock

EBITDA Margin

2024 26.50% 20.17%
2025
22.33% 15.73%
Unlock
2026
27.84% 24.68%
Unlock
2027
35.60% 27.87%
Unlock
2028
37.88% 6.40%
Unlock
2029
42.28% 11.62%
Unlock

19 Neurocrine Biosciences, Inc. Analysts have issued a net profit forecast 2025. The average Neurocrine Biosciences, Inc. net profit estimate is

$399m
Unlock
. This is
21.95% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$586m 79.33%
Unlock
, the lowest is
$252m 22.80%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $327m 33.20%
2025
$399m 21.95%
Unlock
2026
$597m 49.66%
Unlock
2027
$828m 38.67%
Unlock
2028
$1.0b 24.31%
Unlock
2029
$1.1b 10.44%
Unlock

Net Margin

2024 13.88% 6.72%
2025
15.03% 8.25%
Unlock
2026
19.43% 29.27%
Unlock
2027
23.70% 21.98%
Unlock
2028
26.15% 10.34%
Unlock
2029
27.52% 5.24%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ 3.29 4.01
33.20% 21.88%
P/E 26.57
EV/Sales 3.76

19 Analysts have issued a Neurocrine Biosciences, Inc. forecast for earnings per share. The average Neurocrine Biosciences, Inc. EPS is

$4.01
Unlock
. This is
21.88% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$5.90 79.33%
Unlock
, the lowest is
$2.54 22.80%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $3.29 33.20%
2025
$4.01 21.88%
Unlock
2026
$6.00 49.63%
Unlock
2027
$8.33 38.83%
Unlock
2028
$10.35 24.25%
Unlock
2029
$11.43 10.43%
Unlock

P/E ratio

Current 32.39 42.12%
2025
26.57 17.97%
Unlock
2026
17.75 33.20%
Unlock
2027
12.80 27.89%
Unlock
2028
10.30 19.53%
Unlock
2029
9.32 9.51%
Unlock

Based on analysts' sales estimates for 2025, the Neurocrine Biosciences, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.23 38.43%
2025
3.76 11.19%
Unlock
2026
3.24 13.63%
Unlock
2027
2.85 12.07%
Unlock
2028
2.53 11.23%
Unlock
2029
2.41 4.68%
Unlock

P/S ratio

Current 4.48 37.56%
2025
3.98 11.21%
Unlock
2026
3.43 13.63%
Unlock
2027
3.02 12.07%
Unlock
2028
2.68 11.23%
Unlock
2029
2.55 4.68%
Unlock

Current Neurocrine Biosciences, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Canaccord Genuity
Locked
Locked
Locked Apr 28 2025
Evercore ISI Group
Locked
Locked
Locked Apr 24 2025
HC Wainwright & Co.
Locked
Locked
Locked Apr 22 2025
Needham
Locked
Locked
Locked Apr 15 2025
RBC Capital
Locked
Locked
Locked Apr 14 2025
UBS
Locked
Locked
Locked Apr 04 2025
JP Morgan
Locked
Locked
Locked Mar 26 2025
Analyst Rating Date
Locked
Canaccord Genuity:
Locked
Locked
Apr 28 2025
Locked
Evercore ISI Group:
Locked
Locked
Apr 24 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 22 2025
Locked
Needham:
Locked
Locked
Apr 15 2025
Locked
RBC Capital:
Locked
Locked
Apr 14 2025
Locked
UBS:
Locked
Locked
Apr 04 2025
Locked
JP Morgan:
Locked
Locked
Mar 26 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today